Nanobiotix (LTS:0QAV) LT-Debt-to-Total-Asset: 1.34 (As of Dec. 2025)


LTS:0QAV Nanobiotix SA LTS:0QAV
28 GF Score
Price €35.28
! 3 Warning Signs
View Full Analysis

What is Nanobiotix LT-Debt-to-Total-Asset?

Nanobiotix LTS:0QAV +1.15% 28 LT-Debt-to-Total-Asset is 1.34 as of Dec. 2025. GuruFocus rates LTS:0QAV with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nanobiotix's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 1.34.

Nanobiotix's long-term debt to total assets ratio increased from Dec. 2024 (0.68) to Dec. 2025 (1.34). It may suggest that Nanobiotix is progressively becoming more dependent on debt to grow their business.

Nanobiotix  (LTS:0QAV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nanobiotix LT-Debt-to-Total-Asset Related Terms

Nanobiotix LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Nanobiotix's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanobiotix LT-Debt-to-Total-Asset Chart

Nanobiotix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.81 0.49 0.68 1.34

Nanobiotix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.51 0.68 1.03 1.34
LTS:0QAV
28GF Score
Nanobiotix SA LTS:0QAV
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanobiotix LT-Debt-to-Total-Asset Calculation

Nanobiotix's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=91.01/67.76
=1.34

Nanobiotix's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=91.01/67.76
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 1.34 mean?
Nanobiotix (LTS:0QAV) has a LT-Debt-to-Total-Asset of 1.34 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Nanobiotix and its competitors.
Is Nanobiotix's LT-Debt-to-Total-Asset too high?
Nanobiotix's current LT-Debt-to-Total-Asset is 1.34. Overall, Nanobiotix has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Nanobiotix's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Nanobiotix's LT-Debt-to-Total-Asset of 1.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Nanobiotix and its competitors. Nanobiotix's current LT-Debt-to-Total-Asset is 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanobiotix stock overvalued right now?
Nanobiotix (LTS:0QAV) has a current LT-Debt-to-Total-Asset of 1.34. The current LT-Debt-to-Total-Asset is 1.34. Nanobiotix's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Nanobiotix (LTS:0QAV), the current LT-Debt-to-Total-Asset is 1.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanobiotix Business Description

Address 60 Rue de Wattignies, Paris, FRA, 75012
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
28GF Score

Get the complete analysis for LTS:0QAV

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.28
Price